So I read that, and honestly, if it's supposed to make a compelling case for the NASDAQ move, I wasn't convinced.
It probably reads OK to people who don't know the company, but it really doesn't say what the benefit would be. "Will it raise capital" asks the article and if so how much?"
Wrong question, people: the question is "what for?"
Let me put on my Eddy De Bono Black Hat and play devil's advocate, and maybe ask the sort of questions that someone might ask if they're not just writing a puff piece.
The company sells itself- and prides itself- on being self funding. Given that the revenue is likely to increase substantially within the next two years, is any sort of raise really necessary? I know Prostact will be expensive but surely the company can cover that.
It is not clear to me that the factors limiting to the speed of implementing the therapeutics program are simply a matter of access to capital. There look to be limits in the availability of expertise and of test subjects. These can maybe be ameliorated by going to multiple sites (which they'll be doing with Prostact) but there are risks and potential inefficiencies that go with that.
If they raise because it gives them further opportunities that's one thing. If they raise because "it will make the current program go faster" then I'm not convinced.
Given that the company has had no trouble dealing with the big cheeses (Lilly) and doing deals on smaller companies (or buying them outright) do they need to go to the US to make deals? And surely it wouldn't be needed for better clinical/ scientific access, that seems to be going just fine.
If the company is looking to get bought out (though hopefully at a higher price than the examples given in the article) does being in the US really matter? It's not like foreign companies have difficulties buying Australian.
Look, maybe going to the NASDAQ is a good idea, but maybe it's a testament to the quality(?) of Australian mainstream financial journalism that I'm now much more negatively disposed to the idea than before.
- Forums
- ASX - By Stock
- AFR - Why $3b Aussie darling Telix needs to grow wings
So I read that, and honestly, if it's supposed to make a...
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.05 |
Change
-0.190(1.25%) |
Mkt cap ! $4.973B |
Open | High | Low | Value | Volume |
$15.25 | $15.46 | $15.01 | $19.15M | 1.257M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3385 | $15.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.16 | 8704 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3385 | 15.010 |
6 | 6009 | 15.000 |
1 | 8651 | 14.990 |
1 | 1879 | 14.980 |
3 | 3192 | 14.970 |
Price($) | Vol. | No. |
---|---|---|
15.160 | 8704 | 2 |
15.170 | 5300 | 2 |
15.180 | 1693 | 1 |
15.190 | 3421 | 1 |
15.200 | 1000 | 1 |
Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
$15.02 |
  |
Change
-0.190 ( 1.12 %) |
|||
Open | High | Low | Volume | ||
$15.33 | $15.46 | $15.02 | 192620 | ||
Last updated 15.59pm 06/05/2024 ? |
Featured News
TLX (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online